Routine screening for HLA Antibodies in Heart Transplant patients—Does it affect clinical decision making?

Abstract

AbstractBackgroundWe aimed to assess outcomes in patients with and without donor specific antibodies (DSA) and to evaluate the relationship between DSA presence and graft function, cardiac allograft vasculopathy (CAV), and mortality.MethodsThe study population comprises 193 consecutive long‐term heart transplanted (HTx) patients who underwent DSA surveillance between 2016 and 2022. The patients were prospectively screened for CAV through serial coronary angiograms, graft function impairment through serial echocardiograms, and cardiac biomarkers. The patients were followed from the first DSA measurement until death, 5 years follow‐up or right censuring on the 30th of June 2023.ResultsDSAs were detected in 50 patients using a cut‐off at MFI ≥1000 and 45 patients using a cut‐off at ≥2000 MFI. The median time since HTx was 9.0 years [3.0–14.4]. DSA positive patients had poorer graft function and higher values of NT‐proBNP and troponin T, and more prevalent CAV than DSA negative patients. In total, 25 patients underwent endomyocardial biopsies due to DSA presence while another eight patients underwent endomyocardial biopsies for other reasons. Histological antibody mediated rejection (AMR) signs were seen in three biopsies. During a median follow‐up of five years [4.7–5], a total of 41 patients died. Mortality rates did not differ between DSA positive and DSA negative patients (HR 1.2, 95% CI .6–2.4). DSA positive patients were more likely to experience CAV progression than DSA negative patients (HR 2.7, 95% CI 1.5–4.8)ConclusionsRoutine screening reveals DSA in approximately 25% of long‐term HTx patients but is rarely related to histopathological AMR signs. DSA presence was associated with poorer graft function and more prevalent and progressive CAV. However, DSA positive patients had similar survival rates to DSA negative patients.